Heart Failure Hospitalization Risks with DPP-IV Inhibitors: Myth or Reality?

HF Concerns in T2DM

How Should HF Be Evaluated in Patients With T2DM?

The Role of DPP-4 Inhibition in GLP-1 Activity

Experimental Evidence Supporting Beneficial Effects of DPP-4 Inhibition in HF

DPP-4 Inhibitor CV Outcomes Trials: Study Designs

DPP-4 Inhibitor CV Outcomes Trials: Key Inclusion and Exclusion Criteria

DPP-4 Inhibitor CV Outcomes Trials: Prespecified CV Endpoints

DPP-4 Inhibitor CV Outcomes Trials: Primary Endpoint

DPP-4 Inhibitor CV Outcomes Trials: Adjudicated Endpoints

DPP-4 Inhibitor CV Outcomes Trials: Hospitalization for HF

DPP-4 Inhibitors: EXAMINE vs SAVOR vs TECOS Primary Endpoint by History of HF

EXAMINE HF Analysis: Time to Composite of CV Death and Hospitalization for HF by History of HF

HF Endpoints in CV Outcomes Studies

DPP-4 Inhibitor CV Outcomes Trials: Summary

CNODES, A Multicenter Observational Study of Incretin-Based Drugs and HF

Retrospective Cohort Study of HF in T2DM: Risk for Hospitalized HF

FDA Warning and Precaution Labels for the DPP-4 Inhibitors as They Relate to Cardiac Failure ARE NOT EVIDENCE BASED

EMA Labels for the DPP-4 Inhibitors and Cardiac Failure ARE EVIDENCE BASED

Summary

Abbreviations

Abbreviations (cont)